Vivos Therapeutics Inc
NASDAQ:VVOS
Vivos Therapeutics Inc
Accounts Receivables
Vivos Therapeutics Inc
Accounts Receivables Peer Comparison
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
Accounts Receivables
$202k
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
DaVita Inc
NYSE:DVA
|
Accounts Receivables
$2.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Accounts Receivables
$1.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
CVS Health Corp
NYSE:CVS
|
Accounts Receivables
$10.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
2%
|
|
Cigna Corp
NYSE:CI
|
Accounts Receivables
$20.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Accounts Receivables
$2.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
10%
|
See Also
What is Vivos Therapeutics Inc's Accounts Receivables?
Accounts Receivables
202k
USD
Based on the financial report for Dec 31, 2023, Vivos Therapeutics Inc's Accounts Receivables amounts to 202k USD.
What is Vivos Therapeutics Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-20%
Over the last year, the Accounts Receivables growth was -56%. The average annual Accounts Receivables growth rates for Vivos Therapeutics Inc have been -49% over the past three years , -20% over the past five years .